Emerging Threat: Why a Simple Blood Test for Lp(a) Could Revolutionize Heart Disease Prevention
Table of Contents
A previously underrecognized genetic risk factor for heart disease, lipoprotein(a) [Lp(a)], is now poised to undergo widespread screening, potentially transforming cardiovascular health management for millions. Extensive research over the last 15 years, including large-scale genome-wide association studies, has definitively established a causal link between elevated Lp(a) levels and atherosclerotic cardiovascular disease (ASCVD). As many as one in five individuals worldwide may have elevated levels – defined as greater than 125 nmol/L – yet awareness and testing remain strikingly low.
For years, Lp(a) flew under the radar. However, scientists now understand that even its small size belies a substantial health impact. “The science has shown that lifelong exposure to elevated Lp(a) levels increases the risk of many forms of ASCVD,” explained a senior researcher familiar with the latest findings. These include coronary artery disease, aortic valve disease, heart failure, ischemic stroke, and peripheral arterial disease, as well as an increased risk of secondary events in those already battling cardiovascular disease.
Understanding Lipoprotein(a) and Its Impact
Lp(a) is a unique LDL-like particle composed of two key proteins: apolipoprotein(a) and apolipoprotein B-100. Beyond its structural components, Lp(a) exhibits inflammatory effects and is considered “proatherogenic,” actively contributing to the development of atherosclerotic plaques in arteries.
What sets Lp(a) apart from more commonly known risk factors like LDL cholesterol is its strong genetic component. Up to 90% of individual variation in plasma Lp(a) levels is determined by genetics, meaning diet, exercise, and statins have limited impact on lowering it. While conditions like hypothyroidism, chronic kidney disease, and post-menopause can cause slight increases, Lp(a) levels generally remain stable after age five.
A Shift in Guidelines: From Selective to Universal Screening
Medical guidelines surrounding Lp(a) testing have undergone a significant evolution. In 2018, the American Heart Association/American College of Cardiology began recommending selective screening for high-risk individuals – men under 55 and women under 65 with a prior cardiovascular event, those with a family history of premature heart disease or elevated Lp(a), and individuals with very high LDL cholesterol (190 mg/dL or higher).
However, experts quickly recognized the limitations of this approach. Individuals with high Lp(a) are often asymptomatic for decades, allowing the disease to progress silently. Identifying at-risk family members is also challenging due to the lack of widespread testing.
This led to a pivotal shift. In 2024, the National Lipid Association (NLA) issued a scientific statement recommending that all adults be screened for Lp(a) at least once in their lifetime. This guidance aligns with recommendations from the European Society of Cardiology (ESC), further solidifying the call for universal testing to better assess overall cardiovascular risk. The bulk of these tests will likely be ordered by primary care physicians and cardiac specialists.
The Importance of Molarity-Based Assays
Alongside broader screening recommendations, the NLA statement emphasizes the importance of measuring Lp(a) in molar units (nmol/L) rather than traditional mass-based units (mg/dL). Apo(a) isoforms within Lp(a) vary considerably in size, which can skew mass-based measurements and lead to inaccurate results. Research indicates that the concentration of Lp(a) particles – the number of particles per volume of blood – is more strongly associated with ASCVD risk than particle size.
Fortunately, advancements in diagnostic technology are addressing this issue. In January 2025, the first in vitro diagnostic (IVD) test reporting Lp(a) concentration in molar units received FDA clearance. This new test, conducted via routine blood draw and analyzed on a fully automated system, promises to enable high-volume testing comparable to current lipid panels.
Why Screen the General Population? The Numbers Tell the Story
A retrospective analysis of health records from 70 million adults in America, published in May 2025, revealed that only 0.1% had undergone Lp(a) testing. Of those 70,000 individuals tested, approximately 21.4% were found to have elevated levels – consistent with previous estimates. “Clearly, we have a long way to go,” one analyst noted.
However, the genetic basis of Lp(a) offers a unique advantage: testing is only required once in a person’s lifetime. This single measurement can then inform risk mitigation strategies for decades to come. While lifestyle changes won’t directly lower Lp(a) levels, they remain crucial for overall cardiovascular health. Elevated Lp(a) levels may prompt clinicians to set more aggressive targets for other risk factors like cholesterol, blood pressure, and blood glucose. Furthermore, several therapies specifically designed to lower Lp(a) are currently in late-stage clinical development.
Embarking on a New Era of Cardiovascular Monitoring
Determining an individual’s Lp(a) level is the crucial first step in risk mitigation. This will require a collaborative effort from clinicians, medical organizations, and scientific groups across the United States. The American Heart Association (AHA) has already launched the Lp(a) CHC Discovery Project to identify and address barriers to testing within community health centers.
For clinicians eager to learn more, the AHA and other organizations offer a wealth of resources. A simple starting point, according to experts, is understanding one’s own Lp(a) level using an FDA-cleared molarity assay. The widespread adoption of Lp(a) testing represents a significant leap forward in proactive cardiovascular care, offering the potential to identify and mitigate risk before serious events occur.
